BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/5/2025 11:28:03 AM | Browse: 8 | Download: 22
 |
Received |
|
2025-06-04 04:03 |
|
Peer-Review Started |
|
2025-06-04 04:03 |
|
First Decision by Editorial Office Director |
|
2025-06-24 11:03 |
|
Return for Revision |
|
2025-06-24 11:03 |
|
Revised |
|
2025-07-04 02:36 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-09-28 02:45 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-09-28 06:09 |
|
Articles in Press |
|
2025-09-28 06:09 |
|
Edit the Manuscript by Language Editor |
|
2025-10-05 02:41 |
|
Typeset the Manuscript |
|
2025-11-25 05:15 |
|
Publish the Manuscript Online |
|
2025-12-05 11:28 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Minireviews |
| Article Title |
Targeting gut microbiota in liver disease: A pharmacological approach for hepatic encephalopathy and beyond
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Andres Manuel Vargas-Beltran, Stuart Javier Mialma-Omana and Diego Omar Vivanco-Tellez |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Andres Manuel Vargas-Beltran, MD, Department of Hepatology, General Hospital Dr. Manuel Gea Gonzalez, Calz. de Tlalpan 4800, Belisario Domínguez Secc 16, Tlalpan, 14080 Ciudad de México, CDMX, Mexico City 14080, Ciudad de México, Mexico. andresman.vargas@gmail.com |
| Key Words |
Gut microbiota; Hepatic encephalopathy; Gut-liver axis; Probiotics; Fecal microbiota transplantation; Cirrhosis; Fatty liver |
| Core Tip |
The gut microbiota is a key player in the progression of liver diseases, especially hepatic encephalopathy, by influencing ammonia levels, inflammation, and neurocognitive function. This review discusses current and emerging therapies that target the gut-liver axis, including non-absorbable disaccharides, antibiotics, probiotics, synbiotics, postbiotics, and fecal microbiota transplantation. Novel agents such as bile acid modulators and microbiome-targeted molecules are also explored. Modulating gut microbiota may not only alleviate hepatic encephalopathy but also benefit conditions like metabolic dysfunction-associated steatotic liver disease and cirrhosis, facilitating the way for more personalized and effective liver disease management strategies. |
| Publish Date |
2025-12-05 11:28 |
| Citation |
Vargas-Beltran AM, Mialma-Omana SJ, Vivanco-Tellez DO. Targeting gut microbiota in liver disease: A pharmacological approach for hepatic encephalopathy and beyond. World J Gastrointest Pharmacol Ther 2025; 16(4): 110271 |
| URL |
https://www.wjgnet.com/2150-5349/full/v16/i4/110271.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v16.i4.110271 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
